← All trials
NCT04276987
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2020
- Primary completion
- May 31, 2020
- Completion date
- Jul 31, 2020
- First posted
- Feb 19, 2020
- Last posted
- Feb 25, 2020
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiao Tong UniversityLead sponsor
- Fudan UniversityCollaborator
- Cellular Biomedicine Group Ltd.Collaborator
- Jiao Tong UniversityOverall official - principal investigator
- Wuhan Jinyintan Hospital, Wuhan, ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.